Introduction and Background
===========================

Obesity-induced atherosclerosis starts early in life [@B1]. Due to the rise of childhood obesity prevalence, the assessment of determinants of atherosclerosis onset and progression in pediatric cohorts is challenging [@B2].

Arterial disease develops in a non-uniform fashion with arterial stiffening and/or thickening as result of excess adiposity [@B3]. Arterial stiffening is due to a complex pathophysiological process that encompasses adverse structural and functional alterations of the vascular wall. Indeed, the exposure to cardiovascular risk factors \[i.e. high blood pressure, glucose, lipids including oxidized low density lipoproteins (oxLDL), etc.\] promotes overproduction of collagen, reduces quantities of elastin, thus causing unorganized and dysfunctional fiber distribution, infiltration of vascular smooth muscle cells into the intima, and elevated smooth muscle tone [@B3],[@B4]. Instead, arterial thickening is characterized by a steady accumulation of inflammatory molecules, complex lipids, and fibrin. Binding and recruitment of circulating monocytes to the vascular endothelium and further migration into the subendothelial space are key processes for atherosclerosis development also in children [@B5]. Once recruited monocytes infiltrate the intima by the help of cellular adhesion molecules that are expressed on the surface of vascular endothelial cells and whose circulating counterparts are endothelium-derived factors, such as the soluble intercellular adhesion molecule1 (ICAM-1) and E-selectin. This cascade of events causes monocyte differentiation into dendritic cells or CD36 positive macrophages that interact with atherogenic lipoproteins [@B5]. Macrophages CD36+ are important for scavenging and endocytosis of oxLDL and foam cell formation, which, in turn, produce and secrete pro-inflammatory chemokines and cytokines activating a vicious cycle (6). All these molecules released during the atherogenesis process can serve as markers of this condition [@B7]*.*

Pulse wave velocity (PWV) and augmentation index (AIX) are measures of stiffness [@B8] while arterial intima media thickness (IMT) is estimated at the carotid site by B mode ultrasounds [@B9], [@B10].

In recent years, our research goal was the understanding of the origin of cardiovascular disease in overweight and obese children. We observed no association of arterial stiffness and thickness with degree of adiposity or cardiometabolic abnormalities early in preschoolers at the onset of obesity [@B2]. On the contrary, studies reported increased stiffness and thickness in obese adolescents with metabolic complications such as type 2 diabetes (T2D) [@B1], [@B11] and non-alcoholic fatty liver disease (NAFLD) [@B9] as compared to normal-weight controls. Few studies have investigated early atherosclerosis in school-age children but with inconsistent results [@B7], [@B12]-[@B14].

To fill this gap, we investigated brachial PWV, AIX and IMT as estimates of vascular health and examined their correlates with some circulating markers of endothelium dysfunction and inflammation and vessel wall thickening in a sample of obese (body mass index \_BMI z-score\_\>1.645 SD) school-age children (≤10 years-old) and adolescents (\>10 years-old).

Biomarkers were chosen as they represent distinct domains within the context of disturbed vascular biology associated with obesity. E-selectin and ICAM-1 associate with dysfunctional endothelium [@B7]; chemerin, fatty acid-binding protein 4 (FABP-4) and sCD36 are related to altered tissue lipogenesis, and enhanced insulin resistance (IR); sCD36 specifically to vessel wall cholesterol accumulation [@B15]; lipopolysaccharides (LPS) is a marker of low-grade inflammation that can interfere with development and stability of the plaque [@B16]; oxLDL is a signature of oxidative stress; fetuin is related to the risk of developing non-alcoholic fatty liver disease (NAFLD).

Hence, aim of the present study was to investigate vascular phenotypes and circulating markers of disturbed vascular biology in obese school-age children as compared to adolescents in a cross-sectional assessment. Association with metabolic syndrome (MetS) and single metabolic disturbances among high blood pressure, dyslipidemia, impaired glucose tolerance (IGT) and NAFLD was investigated.

Data Description
================

Patients
--------

One-hundred twenty-three obese children (N=55) and adolescents (N=68) were enrolled among those consecutively referred for overweight and/or obesity by general pediatricians to the Units of Clinical Nutrition and Endocrinology at the \'\'Bambino Gesu\'\' Hospital (OPBG) between July 2012 and 2013. Children were randomly selected among those participating in the study "Profiling the genetic risk of complex diseases in the Italian population" which aims at identifying genetic profiles associated with increased risk of IGT [@B17].

Inclusion criteria were age ranging from 6 to 17.8 years; obesity (BMI z-score \>1.645 SD), no previous treatment for obesity, no systemic and endocrine disease, no use of medication, alcohol or recreational drug.

Ethical Statement
-----------------

The study protocol conformed to the 1975 Declaration of Helsinki and specifically to guidelines of the European Convention of Human Rights and Biomedicine for Research in Children. It was approved by the OPBG Ethics Committee.

Written informed consent was obtained from the parents/legal guardians, and patients\' data was treated to guarantee confidentiality.

Anthropometric measurements and clinical examination
----------------------------------------------------

Weight was measured with an approved scale (90/384/EEC, SECA) with precision of 50 g and periodic calibration. Children were weighed with minimal dress and weight recorded to the last 100 g. Height (without shoes) was measured with a Holtain\'s stadiometer with precision of 0.1 cm and registered with approximation of 0.5 cm. The body mass index (BMI) and the BMI-z score (SDS) were calculated based on Italian age and sex-related standards [@B18]. Waist circumference (WC) was measured midway between the superior border of the iliac crest and the lower most margin of the ribs at the end of normal expiration and waist to height ratio (WTHR) calculated as rough estimate of visceral obesity.

Systolic (SBP) and diastolic blood pressure (DBP) were measured three times while the subjects were seated using an automated oscillatory system and appropriately sized arm cuffs (Dinamap; Criticon Inc), and the measurements were averaged.

Blood tests and biochemical assays
----------------------------------

All the participants were asked to refrain from intensive physical activity in the 3 days prior to the study. Fasting blood samples were drawn after 8-12 h fast and concentrations of triglycerides (TG), high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL) cholesterol, and total cholesterol (TC) were assessed by using colorimetric kits (Roche/Hitachi Modular systems P/S, Can 433, Milan, Italy). Alanine aminotransferase (ALT), aspartate aminotransferase (ASP), γ -glutamyltransferase (γ-GT) and uric acid (UA) were measured (ADVIA 1650 Chemistry System; Bayer Diagnostics, Erlangen, Germany). Glucose was measured by the glucose oxidase technique (Cobas Integra, Roche, Rotkreuz, Switzerland) and insulin by chemiluminescent immunoassay method (ADVIA Centaur Analyzer; Bayer Diagnostics; Erlangen, Germany) on two fasting blood samples. For the measurement of circulating molecules blood samples were centrifuged at 8000 RPM for 12 minutes and stored at -80°C pending further analysis. Samples were thawed only once and measured according the manufacturer\'s procedures by using the following enzyme-linked immunosorbent assays (ELISA) kits: sICAM 1, sE-selectin, Fetuin, FABP4 (BioVendor, Modřice, Czech Republic); Chemerin, Lipocalin, (RayBiotech Inc, GA, USA); LPS by Limulus amoebocyte lysate chromogenic endpoint assay (Hycult Biotechnology, The Netherlands); oxLDL (Immundiagnostik AG, Germany; intra-assay-coefficient of variation 5.2 %).

Plasma sCD36 was measured by a well-established in-house ELISA essentially as described elsewhere [@B15]. Patients underwent standard oral glucose tolerance test (OGTT) and glucose (G) and insulin (I) levels were at baseline and every 30 min for 120 min.

Definition of metabolic abnormalities and calculation of metabolic indexes
--------------------------------------------------------------------------

Dyslipidemia was diagnosed as value of TC and/or TG higher than the 95th percentile and/or HDL-cholesterol lower than the 5th for age and sex [@B2], [@B17]. Hypertension (HT) was defined as SBP or DBP exceeding the 95th percentile for age, sex, and height [@B2], [@B17]. Impaired glucose tolerance (IGT) was diagnosed as 2-h glucose ≥140 mg/dl following the OGTT. NAFLD was suspected in the presence of ALT \>40 U/l and ultrasound evidence of increased liver brightness after ruling out other conditions causing abnormalities of liver enzyme according to a standardized protocol [@B2].

Patients were grouped as affected by obesity with none of the metabolic abnormalities or obesity plus one or more abnormalities of the metabolic syndrome (MetS group) among hypertension, dyslipidemia (high TG or TC and/or low HDL-cholesterol), IGT and NAFLD.

HOMA-IR was calculated as average on two blood samples as \[fasting glucose (mg/dl) × fasting insulin (µU/ml)/405\]. Insulin sensitivity index (ISI) was calculated as:

\[ISI =10,000/√(fasting glucose×fasting insulin)×(mean glucose×mean insulin)\]

The TG to HDL-cholesterol ratio was calculated and a value ≥2.2 was considered as risky ("Atherogenic ratio") [@B19]. Non HDL-cholesterol was calculated as TC minus HDL-cholesterol.

Arterial stiffness measures
---------------------------

Applanation tonometry was performed using SphygomoCor^®^ (Atcor Medical, Sydney, NSW, Australia) with the subject in the supine position as described in Haller *et al.* [@B20]. The pulse wave of intermediate-sized arteries was recorded from the radial artery of the right arm (brachial PWV) with a high-fidelity micromanometer (SPC-301; Millar Instruments, Houston, TX, USA). All readings recorded met the manufacturer\'s quality control standards integrated into the software package. AIX was calculated as the difference between the second (caused by wave reflection) and the first systolic peak (caused by ventricular ejection). The average of three consecutive readings, each consisting of at least 20 sequentially recorded waveforms, was used for the analyses. AIX was adjusted for heart rate (AIX\@75).

Measurement of Carotid IMT
--------------------------

Carotid artery ultrasound was performed (Siemens ACUSON X700™ equipped with VF10-5 linear array transducer, Siemens Erlangen, Germany). Subjects were placed in the supine position and images were taken from longitudinal sections of the carotid artery in a standardized fashion. Scans were stored digitally on the internal hard disk of the ultrasound system for subsequent analysis. The maximum value of IMT was taken as described in Pacifico *et al.* [@B10].

Statistical Analysis
--------------------

Data are presented as median and inter-quartile range (IQR), unless otherwise stated (means and standard errors in figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) or as number and percentage. Distributions of continuous variables were examined for skewness and kurtosis and were logarithmically transformed when appropriate before analysis (G120, I120, SBP, DBP, non-HDL-cholesterol, TG/HDL ratio, PWV, oxLDL, HOMA, ISI, LPS, lipocalin, chemerin, FABP4). Differences between groups were tested for significance using independent samples t-test and analysis of variance (ANOVA) for quantitative variables, and chi-square test for qualitative variables. Pearson\'s correlation and linear regression coefficients were used to examine relationships between variables. The strength of these relations was expressed as coefficient and *p* value.

Stepwise linear regression analysis was performed to identify predictors of PWV.

A *p* value of \<0.05 was considered statistically significant. Statistical analyses were performed using the Statistical Package for Social Sciences (version 11.5; SPSS Inc., Chicago, IL, USA).

Results
=======

Cardiovascular risk factors in children vs. adolescents
-------------------------------------------------------

Adolescents had significantly different median BMI compared to children \[28.9 (4) vs. 26.02 (4); *p*\<0.0001\] and WHTR \[0.56 (0.06) vs. 0.59 (0.06), respectively; *p*=0.002\] but not different BMI z-score. The same was for fasting glucose \[79 (10) vs. 76 (11) mg/dl; *p*=0.037\]; serum uric acid \[7.9 (3.10) vs. 6.7 (2.4) mg/dl; *p*=0.002\]; LDL-C \[6 (2.2) vs. 5.3 (1.5) mg/dl; *p*=0.037\] and non-HDL-cholesterol \[97 (37) vs. 103 (37) mg/dl; *p*=0.02\]; and SBP \[105 (11) vs. 101 (7) mm/Hg; *p*=0.005\].

No difference was found in circulating CVD biomarkers between age-groups.

Median PWV was significantly different in adolescents as compared to children \[7.9 (3.1) vs. 6.7 (2.4) m/sec; *p*=0.02\] while *AIX\@75* and*~M~*IMT were not.

~M~IMT, PWV, AIX\@75 and circulating biomarkers of CVD risk in children and adolescents according to the MetS status
--------------------------------------------------------------------------------------------------------------------

Number of children and adolescents with and without metabolic abnormalities was not significantly different (*p*=0.3). Metabolic abnormalities included high blood pressure (N=11, 8.9) and TG (N=19; 15.4%); low HDL-cholesterol (N=40; 32.5%); IGT (N=12, 9.7%); NAFLD (N=20; 16.2%) and prevalence of any single metabolic abnormality was not different in age-groups except for high TG (15% vs. 4%; *p*=0.002). Forty patients (32.5%) had HDL/TG ratio \>2.2.

We reported in **Table [1](#T1){ref-type="table"}**anthropometrics, clinical characteristics and laboratory parameters of the whole sample (N=123; 61 males, 49.6%); of children versus adolescents with simple obesity (N=51, 41.5%) and of patients who were complicated by one or more metabolic abnormalities.

In the overall sample, median HDL-cholesterol (p\<0.0001), TG/HDL-cholesterol ratio (p\<0.0001); triglycerides (p\<0.0001), fasting (p=0.01) and post load glucose (p\<0.0001), uric acid (p=0.002), ALT (p=0.002) and AST (p\<0.0001), HOMA-IR (0.009) ISI (0.001), PWV (p=0.03) and oxLDL (p=0.05) were statistically higher in cases with compared to patients without MetS abnormalities. Same differences were observed statistically significant in age-groups except for PWV that was higher only in adolescents with MetS abnormalities as compared to peers without (Table [1](#T1){ref-type="table"}). Stepwise liner regression model identified BMI z-score as the best predictor (R^2^=0.290; β= 0.578; p\<0.0001) of PWV in adolescents while TG/HDL ratio, PAS, ISI, uric acid and ALT did not.

sCD36 levels were significantly (p=0.05) higher in children with MetS than in peers with no abnormalities but not in adolescents.

**Table [3](#T3){ref-type="table"}** shows main correlations among atherogenic estimates. ICAM and E- selectin were significantly correlated each other (rho=0.289; *p*=0.006) as were sCD36 and oxLDL (rho=0.471; *p*\<0.0001). sCD36 was the solo whose concentration was correlated to HOMA-IR (rho=0.197; *p*=0.03).

~M~IMT, and circulating biomarkers of CVD risk in cases with atherogenic ratio, high blood pressure, IGT and NAFLD
------------------------------------------------------------------------------------------------------------------

Cases with TG/HDL-C ≥ 2.2 (N=40) displayed circulating levels of sCD36 significantly higher than others \[0.165 (0.010) vs. 0.24 (0.017) a.u., *p*=0.02\]; oxLDL \[156 (38.3) vs. 86 (18.6) mg/dl, *p*=0.05\] (**Figure [1](#F1){ref-type="fig"}),**panels A and B), and HOMA-IR \[2.62 (1.6) vs. 1.89 (1.9), *p*=0.03\].

Cases with HT (N=11) showed significantly higher levels of sCD36 \[0.26 (0.18) vs. 015 (0.17) a. u., *p*=0.05\] and oxLDL \[192 (67) vs. 69 (142) mg/dl, *p*=0.006\] (Figure [1](#F1){ref-type="fig"}, panels C and D)\].

IGT patients had significantly higher levels of lipocalin \[19.8 (5) vs. 17.3 (1) vs. ng/ml; p=0.04\].

Tertiles stratification of ~M~IMT, PWV, and AIX\@75
---------------------------------------------------

Distribution of anthropometrics and circulating biomarkers of disturbed vascular biology were evaluated across tertiles of ~M~IMT, PWV and AIX\@75. BMI \[26.0 (0.47) vs. 27.9 (0.41) vs. 29.5 (0.78) kg/m2, p\<0.0001\] and BMI z-score \[1.93 (0.067) vs. 2.22 (0.05) vs. 2.41 (0.08) SDS; p\<0.0001\] were significantly different across PWV tertiles (P\<0.0001 for both). Figure [2](#F2){ref-type="fig"} shows mean values of TC, non HDL-cholesterol, oxLDL, sCD36, ICAM1, whose distributions were significantly different across tertiles of AIX\@75.

Discussion
==========

In the recent years, our research goal became the understanding of the origin of cardiovascular disease associated with early onset obesity. Metabolic abnormalities such as high blood pressure, dyslipidemia, impaired glucose metabolism and liver steatosis are diagnosed in preschoolers with overweight not later than one year after the onset of excess weight. At that time, arterial thickness and stiffness did not correlate with the degree of adiposity or metabolic derangement [@B2].

Findings of the present investigation suggest that associations between arterial thickness and/or stiffness with metabolic abnormalities manifest later in childhood and adolescence. They may be, however, weak at first (see Table [3](#T3){ref-type="table"}) and their early recognition requires use of different techniques, in our case tonometry and ultrasounds combined with circulating biomarkers to look at different features and pathogenic culprits of the impaired vascular biology associated with obesity.

Cardiovascular risk factors in children vs. adolescents
-------------------------------------------------------

In the present study, significant differences were observed in lipid profile, uric acid and blood pressure and brachial PWV between age-groups. No differences were found in circulating molecules associated with impaired vascular biology, AIX\@75 and IMT~M~.

While the degree of obesity as measured by the BMI z-score was not different, the BMI and the waist to height ratio were significantly higher in children than in adolescents. The pubertal development influences the body shape and adiposity and indeed, large epidemiological studies show that prevalence of high WTHR is significantly higher in children than in adolescents [@B21].

While differences in the lipid profile between children and adolescents may be expected owing to the different age-dependent intake of carbohydrates and hence limiting their ability to serve as marker of risk [@B22], PWV seems depending on aging and body growth in a way that is mostly independent of the other cardiovascular risk factors. Aortic PWV, indeed, increased on average by 1 m/s from 3 to 18 years of age being largely influenced by the body growth at the passage from childhood to adolescence [@B23]. In a large study of 573 healthy children, the relationship between PWV and BMI was independent of other CV risk factors including degree of IR as estimated by the HOMA-IR [@B24].

PWV vs. AIX\@75
---------------

In our series too, brachial PWV was correlated with BMI in the whole sample and in adolescents being higher in cases with metabolic abnormalities respect to those without. Conversely, in children we observed weak but significant correlation of traditional and not traditional CVD humoral markers with AIX\@75 (Table [3](#T3){ref-type="table"}).

PWV is a direct measure of stiffness while AIX is an indirect measure. AIX reflects the combined effect of magnitude and timing of the reflected waves that, in turn, are preliminarily related to peripheral vascular resistance and distensibility of the aortic wall [@B3]. Since it reflects the combination of all these features associated with obesity, AIX might represent a marker of altered vascular health more precocious than increased PWV [@B3]. Brachial PWV is a suitable stiffness index of intermediate-sized arteries and AIX of resistance arteries [@B3].

The relationship between PWV and AIX remains matter of debate. In our series, there was no correlation between the two parameters as previously seen in a study of hypertensive adults [@B25]. Increased stiffness may precede thickening hence altering the endothelial function, promoting the decline of nitric oxide (NO) synthase activity, favoring further arterial stiffness and increased thickness. [@B4]. In that, the lack of association between measures of stiffness and thickness does not surprise and, indeed, it confirms previous findings in healthy young individuals from the Cardiovascular Risk in Young Finns Study [@B26]. The study by Tounian *et al.* [@B7] also found no difference in IMT but increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children.

Stiffness and thickness in youth
--------------------------------

Age [@B23], clinical [@B25] and preclinical hypertension [@B1], [@B25], LDL-cholesterol, hyperglycemia [@B1], [@B29] and inflammation are known risk factors for arterial stiffness [@B28] and increased IMT in pediatric ages [@B12]-[@B14]. Age, sex and body growth influenced both IMT and PWV.

Cross-sectional studies of normal-weight 7-years-old children [@B14], overweight vs. normal-weight prepubertal individuals [@B13] and overweight young people [@B12], all demonstrated that increase of IMT occurring in childhood obesity is strongly related to the cardiovascular risk factors of obesity.

Among risk factors, impaired glucose metabolism arose as one of the most important promoting factor of both increased thickness [@B29] and stiffness in youth [@B29],[@B30].

In our series, less than 10% of patient presented with high blood pressure or IGT and this might have affected results. We cannot exclude that NAFLD was underestimated [@B31] in the present study since we considered as affected exclusively cases with ultrasound evidence of liver brightness and ALT levels higher than 40 UI/L. In keeping with a previous study of ours, no correlation was found between IMT and ALT levels [@B9].

Circulating oxLDL and sCD36 and LPSs
------------------------------------

In our study, we focused on novel possible markers of CVD to investigate their association with arterial thickness and brachial stiffness. We excluded C-reactive protein since the lack of significant association with early onset of CVD [@B2], [@B32] and increased femoral and brachial stiffness [@B29] found in previous studies. We found of particular interest oxLDL, sCD36 and LPS since their involvement in the pathogenesis and progression of atherosclerotic lesions.

oxLDL can promote the progression from increased stiffening to thickening in several ways; by leading to endothelial dysfunction through the angiotensin II type 1 receptor, through the quenching of NO and the decrease of its production and by the promotion of foam cell formation. In children, oxLDL levels were inversely related to the arterial nitrate-mediated dilatation likely being involved in early atherosclerosis [@B26]. In other studies, oxLDL was associated with the incidence of MetS, the sum of obesity, hyperglycemia, and hypertriglyceridemia and the presence of T2D compared to normal-weight controls [@B27].

CD36 is a multifunctional membrane protein expressed by many cell types and important for fat uptake in the gut and accumulation in the liver. It serves as scavenger receptor for oxLDL and macrophage CD36 plays a crucial role in arterial cholesterol accumulation and early CVD [@B6]. sCD36, its non-cell bound circulating form, reflects tissue CD36 expression [@B15]. Circulating levels of sCD36 were associated with increased insulin resistance and arterial thickness in the healthy population of the Relationship between Insulin Sensitivity and Cardiovascular disease study [@B15]. Very recently, it a decrease of sCD36 in weight losing children in parallel with the amelioration of their IR and hepatic steatosis was reported [@B33]. The association between arterial dysfunction and sCD36 and oxLDL presented here supports cholesterol accumulation as an early process in the origin of obesity related CVD. Mechanistically, insulin resistance increases CD36 expression [@B15] and thereby the risk of CD36 mediated cholesterol accumulation in arteries.

LPSs have a role in the pathogenesis of CVD by promoting the release of proinflammatory cytokines, leading to severe endothelial dysfunction, plaque formation and rupture, oxidation of LDLs, and thrombogenesis as extensively reviewed elsewhere [@B16], [@B34].

In our series, there were weak but significant correlations between levels of these molecules and AIX\@75 and/or IMT~M~. Nevertheless, these molecules did not perform better than known risk factors such as blood lipids and their ratio. Recent literature has put emphasis on the HDL to triglyceride ratio as risk factor and even marker of organ damage in obese youth [@B19].

Strength and weakness of the study
----------------------------------

The strength of our study is the deep phenotyping with an extensive list of arterial functional, anthropological and biochemical parameters evaluated in the obese children and adolescents in a "quasi-longitudinal" (study of children vs. adolescents) study by the use of two different techniques to assess early atherosclerosis and the matching with circulating levels of various molecules that have been associated with impaired vascular biology. Major caveats are the lack of normal-weight controls, the cross-sectional design, the limited number of patients with each comorbidity that may have underpowered results; and the lack of information on the pubertal status that influences vascular structure and response [@B7]. Furthermore, we measured peripheral stiffness and aotic stiffness that has the best association with the CVD risk. We are also aware that measurement of oxLDL may be not always reliable as suggested by data distribution in the present series.

Despite weakness, findings of the present study can be informative for larger population studies of cardiovascular disease in young obese patients.

Conclusion
==========

Our study responds to the need of investigations of early CVD associated with obesity in youth. Findings confirm that stigmata of atherosclerosis accompany obesity since its onset. Their recognition may require, nonetheless, simultaneous use of different measures and markers.
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###### 

Anthropometrics and cardiometabolic parameters of obese children and adolescents according to the metabolic syndrome (MetS) status.

                                Whole sample (N=123)   Children (N=55)   Adolescents (N=68)                  
  ----------------------------- ---------------------- ----------------- -------------------- -------------- -----------------
  Age (years)                   10.4 (3)               9 (1.09)          8.6 (1.57)           11.4 (2.95)    12.5 (3.24)
  Sex (M/F)                     58/65                  9/9               15/22                15/15          19/19
  Body weight (kg)              59.1 (20)              50 (14)           48.5 (14)            60.8 (15)      71 (26)
  BMI z-score (SDS)             2.20 (1)               2.06 (0)          2.28 (0.05)^a^       2.02 (0)       2.36 (1)^a^
  WTHR                          0.58 (0.06)            0.59 (0.05)       0.60 (0.06)          0.57 (0.07)    0.56 (0.06)
  Total cholesterol (mg/dl)     145 (40)               147 (51)          151 (43)             146.5 (47)     139 (44)
  HDL-cholesterol (mg/dl)       44 (16)                47 (7)            41 (9)^a^            50 (14)        36 (12)^c^
  TG/HDL-cholesterol ratio      1.57 (0.98)            1.39 (0.36)       1.80 (1.08)^b^       0.96 (0.52)    1.90 (1.03)^c^
  LDL-cholesterol (mg/dl)       86 (35)                88 (46)           91 (26)              78 (40)        83 (36)
  Non-HDL Cholesterol (mg/dl)   99 (33)                102 (47.5)        106 (37)             94.5 (39.7)    98 (36)
  Triglycerides (mg/dl)         68 (36)                66 (12)           76 (49)^\*^          55 (27)        76 (45)
  Fasting glucose (mg/dl)       78 (10)                74 (9.8)          79 (12.5)            74 (11.5)      81 (10)^\*\*\*^
  Post load glucose (mg/dl)     115 (20)               114.5 (18.5)      115 (26.5)^\*^       101.5 (22.3)   124 (19)^\*\*^
  Uric acid (mg/dl)             5.5 (2)                4.8 (0.9)         5.3 (2.0)            5.50 (1.7)     6.4 (2.4)^\*\*^
  ALT (uUI/ml)                  22 (12)                23 (9)            24 (7)^\*\*^         17.5 (7)       25 (27)^\*\*^
  HOMA-IR                       2.2 (0.2)              1.80 (1.4)        2.4 (1.5)            1.7 (2.1)      3.3 (3.2)^\*^
  ISI                           3.8 (3.4)              5.3 (3)           3.68 (2.8)^\*^       4(2.7)         2.57 (3.7)^\*^
  SBP (mm/hg)                   104 (9)                102 (8)           101 (9)              103.5 (11)     106 (15)^\*\*^
  DPB (mm/hg)                   69 (11)                68 (6)            69 (14)              70 (11)        70 (12)
  PWV (m/s)                     7.4 (2.5)              7.1 (1.75)        6.4 (2.55)           7.4 (1.55)     8.1 (3.10)^\*^
  AIX\@75 (%)                   5.75 (3.50)            5.87 (3.69)       6.5 (2.75)           6 (3.7)        5.50 (3.5)
  ~M~IMT (mm)                   0.5 (0.10)             0.5 (0.2)         0.5 (0.2)            0.5 (0.09)     0.5 (0.10)

^a^Data are expressed and median and interquartile range in parentheses. *P* refers to the statistical significance at the independent samples t-test between patients with and without abnormalities of the metabolic syndrome (MetS) belonging to the two class-age groups. ^\*^ p≤0.05; ^\*\*^ ≤0.01; ^\*\*\*^≤0.0001. ALT: alanine aminotransferase; AIX\@75: augmentation index normalized by heart rate; BMI: body mass index; HOMA-IR: homeostatic model assessment of insulin resistance; ISI: insulin sensitivity index; LDL: low density lipoprotein; ~M~IMT: maximum intima media thickness; MetS: metabolic syndrome; SBP and DBP: systolic and diastolic blood pressure; PWV: pulse wave velocity; TG/HDL-cholesterol: triglycerides to HDL-cholesterol; WHTR: waist to height ratio.

###### 

Circulating markers of cardiovascular disease in obese children and adolescents and without major metabolic syndrome (MetS) abnormalities

                            Whole sample (N=123)   Children (N=55)   Adolescents (N=68)                 
  ------------------------- ---------------------- ----------------- -------------------- ------------- -----------
  Chemerin (ng/ml)          1639 (58)              1828 (56)         1725 (68)            1659 (63)     1795 (57)
  E-selectin (ng/ml)        11 (0.82)              7.81 (15)         9.16 (8)             14 (13)       11.2 (11)
  ICAM1 (ng/ml)             289 (7.2)              282 (149)         291 (68)             286 (61)      280 (108)
  FABP4 (ng/ml)             19.3 (1.23)            16.2 (13)         16.4 (16)            15.3 (20)     13.3 (16)
  Fetuin (µg/ml)            1.09 (0.041)           1.25 (1)          1.12 (0)             1.08 (0)      0.85 (1)
  Lipocalin (ng/ml)         25.51 (3.9)            17.34 (1)         17.34 (21)           15.9 (2)      17.3 (2)
  LPS (EU/ml)               12.6 (0.88)            12.25 (8)         42 (74)              11.43 (8)     9.53 (5)
  oxLDL (µg/ml)             198 (22)               42 (74)           75 (150)             85 (88)       98 (343)
  sCD36 (arbitrary units)   0.209 (0.01)           0.13 (0.06)       0.17 (0.23)^\*^      0.14 (0.14)   0.2(0.16)

^b^Data are expressed and median and interquartile range in parentheses. P refers to the statistical significance at the independent samples t-test between patients with and without abnormalities of the metabolic syndrome (MetS) belonging to the two class-age groups. ^\*^p≤0.05. ICAM1:soluble intercellular adhesion molecule1; FABP4: fatty acid-binding protein 4; LPS: lipopolysaccharide.

###### 

Correlates of PWV, Aix\@75 and ~M~IMT

                                Whole sample (N=123)   Children (N=55)   Adolescents (N=68)                                                                         
  ----------------------------- ---------------------- ----------------- -------------------- ----------- ------------- ------------- --------------- ------------- -----------
  Age (years)                   0.192^\*^              \-                \-                   \-          \-            \-            \-              \-            \-
  BMI z-score                   0.431^\*\*\*^          \-                \-                   0.316^\*^   \-            \-            0.513^\*\*\*^   0.276^\*^     \-
  Uric acid (mg/dl)             0.191^\*^              \-                \-                   0.329^\*^   \-            \-            \-              0.266^\*^     \-
  Total Cholesterol (mg/dl)     \-                     0.216^\*^         \-                   \-          \-            \-            \-              \-            0.251^\*^
  LDL-cholesterol (mg/dl)       \-                     0.222^\*^         \-                   \-          \-            \-            \-              \-            0.268^\*^
  HDL/TG                        \-                     0.195^\*^         \-                   \-          \-            \-            \-              \-            0.284^\*^
  Non HDL-Cholesterol (mg/dl)   \-                     \-                \-                   \-          0.378^\*\*^   0.368^\*\*^   \-              0.379^\*\*^   0.295^\*^
  LPS(EU/ml)                    \-                     0.242^\*^         \-                   \-          0.341^\*^     \-            \-              \-            \-
  oxLDL (µg/ml)                 \-                     0.238^\*\*^       0.265^\*\*^          \-          0.294^\*^                   \-              \-            0.257^\*^
  sCD36 (a.u.)                  \-                     0.184^\*^         0.278^\*^            \-          0.365^\*^     \-            \-              \-            \-

^c^Statistical significant with ^\*^p\<0.05; ^\*\*^p\<0.01 and ^\*\*\*^p\<0.001. BMI: body mass index; LPS: lipopolysaccharide. PWV: Pulse wave velocity; AIX\@75 augmentation index normalized by heart rate, and ~M~IMT: maximum intima media thickness~.~

[^1]: Competing Interests: A Handberg is the inventor of two patent applications on sCD36 as a biomarker of the metabolic syndrome. The patent IP rights are owned by the Idea\'s Clinic of Aalborg University Hospital. The remaining authors have indicated they have no potential conflicts of interest to disclose. Other authors have indicated they have no financial relationships relevant to this article to disclose.
